Orion - Company Announcement

The Board of Directors of Orion Corporation decided on an incentive plan for key persons

Orion Corporation - Stock Exchange Release




ORION CORPORATION: The Board of Directors of Orion Corporation decided on an
incentive plan for key persons



ORION CORPORATION   STOCK EXCHANGE RELEASE  18 FEB 2010  AT 10.20 AM
EET


The Board of Directors of Orion Corporation decided on an incentive plan for key
persons

The Board of Directors of Orion Corporation has approved a new share-based
incentive plan for the Group key persons. The aim of the Plan is to combine the
objectives of the shareholders and the key persons in order to increase the
value of the Company, to commit the key persons to the Company, and to offer
them a competitive reward plan based on holding the Company's shares.

The new Plan includes earning periods. The Board of Directors will annually
decide on the beginning and duration of the earning periods in 2010, 2011 and
2012. The Board of Directors will decide on the earnings criteria and on targets
to be established for them at the beginning of each earning period. Two earning
periods, calendar year 2010 and calendar years 2010-2012, commenced upon
implementation of the Plan. The prerequisite for participation in the earning
periods 2010 and 2010-2012 and for receipt of reward on the basis of these
earning periods is that a key person holds the Company's shares, as determined
by the Board of Directors. The potential reward of the Plan, for the earning
period 2010, is based on the Orion Group's result development and on fulfillment
of the above-mentioned participation prerequisite, and, for the earning period
2010-2012, on the total return on Orion Corporation class B share.

The potential reward will be paid partly as the Company's class B shares and
partly in cash in 2011, on the basis of the earning period 2010, and in 2013 on
the basis of the earning period 2010-2012. The proportion to be paid in cash
will be used for taxes and tax-related costs arising from the reward to a key
person. The value of reward to be paid on the basis of the Plan during one
calendar year is a key person's gross annual salary multiplied by 1.5, in the
maximum, at the date of the reward payment. Gross annual salary means total
salary together with fringe benefits, excluding annual bonus and long-term
incentive plan. The shares paid on the basis of the earning period 2010 cannot
be transferred during the restriction period, which will end on 31 December
2012. If a key person's employment or service in a Group company ends during the
restriction period, he or she must return the shares given as reward to the
Company without compensation.

After the restriction period the members of the Group Executive Management Board
must hold 50% of the shares paid on the basis of the Plan as follows:  the
President and CEO, as long as the total value of the Company's shares held by
him corresponds to his gross annual salary, and any other member of the Group
Executive Management Board, as long as the total value of the Company's shares
held by him or her corresponds to half of his or her gross annual salary.

The target group of the Plan consists of approximately 30 people. The total
maximum amount of rewards to be paid on the basis of the Plan is 500,000 Orion
Corporation class B shares and a cash payment corresponding to the value of the
shares.


Orion Corporation



Timo Lappalainen             Olli Huotari
President and CEO           SVP, Corporate Functions

Contact person:
Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, GSM +358
50 966 3054





Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi <http://www.orion.fi/>



Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler(®)
pulmonary drugs.

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested
EUR 95 million in research and development. At the end of 2009, the Group had a
total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other
European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.



[HUG#1385875]